Referências
- Coates TD and Wood JC, How we manage iron overload in sickle cell patients. Br J Haematol. 2017 June; 177(5): 703-716
- Hider RC and Hoffbrand AV, The Role of Deferiprone in Iron Chelation. N Engl J Med 2018;379:2140-50
- Children’s Hospital & Research Center Oakland. Standards of Care Guidelines for Thalassemia 2012
- Coates TD. Physiology and pathophysiology of iron in hemoglobin-associated diseases. Free Radical Biology and Medicine 72(2014)23–40
- Beris P, Transfusion and Iron Overload: Where Are the Risks? HAEMA 2019; 10(1):29-38
- Borgna-Pignatti C et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. haematologica 2004;89:1187-1193
- Fung EB et al. Morbidity and Mortality in Chronically Transfused Subjects With Thalassemia and Sickle Cell Disease: A Report From the Multi-Center Study of Iron Overload. American Journal of Hematology (2007) 82:255–265
- Coates TD et al. Management of iron overload in hemoglobinopathies: what is the appropriate target iron level? Ann. N.Y. Acad. Sci. 1368 (2016) 95–106
- Pennell DJ, et al. Cardiovascular Function and Treatment in β-Thalassemia Major. A Consensus Statement From the American Heart Association. Circulation. 2013;128:281-308
- American Society of Hematology. Understanding Sickle Cell Disease. Available at: https://www.hematology.org/-/media/hematology/files/education/clinicians/guidelines-quality/documents/ash-understanding-scd-infographic_2019.pdf?la=en&hash=F96E476D04908727FD74678B5C876266
- National Heart, Lung and Blood Institute. Sickle Cell Disease. Available at: https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease
- Howard J, Sickle cell disease: when and how to transfuse. Hematology 2016
- Ballas SK et al. The effect of iron chelation therapy on overall survival in sickle cell disease and b-thalassemia: A systematic review. Am J Hematol. 2018; 93:943–952
- Sundaram N, et al. Biomarkers for early detection of sickle nephropathy. Am J Hematol. 2011 July ; 86(7): 559–566
- Wang W, et al. Serum Ferritin: Past, Present and Future. Biochim Biophys Acta. 2010 August ; 1800(8): 760–769
- Junqueira FP, et al. Right and left ventricular function and myocardial scarring in adult patients with sickle cell disease: a comprehensive magnetic resonance assessment of hepatic and myocardial iron overload. Journal of Cardiovascular Magnetic Resonance 2013, 15:83
- Muncie HL and Campbell JS. Alpha and Beta Thalassemia. American Family Physician. August 15, 2009 Volume 80, Number 4
- Marengo-Rowe AJ. The thalassemias and related disorders. Proc (Bayl Univ Med Cent) 2007;20:27–31
- Sheth S, Monitoring of Iron Overload in Transfusion-Dependent Thalassemia (TDT). NewYork-Presbyterian Hospital/Weill Cornell Medical Center
- Cappellini MD, et al. Guidelines for the management of transfusion dependent thalassaemia (tdt). Thalassaemia International Federation 2014. 3rd Edition
- Centers for Disease Control al Prevention. Living Well with Sickle Cell Disease. Available at: https://www.cdc.gov/ncbddd/sicklecell/healthyliving-living-well.html
- Baer K, A Guide to Living with Thalassemia. Cooley’s Anemia Foundation in collaboration with the Centers for Disease Control and Prevention
- Sidhu S, et al. Adherence to Iron Chelation Therapy and Its Determinants. IJHOSCR January 2021. 15(1)
- Chou ST, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood advances 28 January 2020; Volume 4, Number 2
- Centers for Disease Control al Prevention. Infections and Sickle Cell Disease. Available at: https://www.cdc.gov/ncbddd/sicklecell/healthyliving-prevent-infection.html
- UCSF Benioff Children’s Hospital Oakland. Northern California Comprehensive Thalassemia Center. Living with Thalassemia. Available at: https://thalassemia.com/nutrition-simple-suggestions.aspx#gsc.tab=0
- Fung EB, et al. Inadequate Dietary Intake in Patients with Thalassemia. J Acad Nutr Diet. 2012 July ; 112(7): 980–990
- Cunningham E. Journal of the Academy of Nutrition and Dietetics. 2016
- PCRM’s Nutrition Guide for Clinicians. Sickle Cell Disease. Available at: https://nutritionguide.pcrm.org/nutritionguide/view/Nutrition%20Guide%20for%20Clinicians/1342072/all/Sickle_Cell_Disease
Caso seja necessário relatar uma reação adversa a um medicamento, consulte seu médico(a) e peça que ele(a) preencha e envie o relato do caso relevante à autoridade sanitária competente, de acordo com os requisitos de farmacovigilância vigentes em seu país. Lembre-se, porém, de que cada paciente pode relatar esses tipos de caso diretamente pelo sistema nacional de notificação de eventos adversos.